Thrombogenics announces publication of positive microplasmin Phase II trial results (News-Medical-Net)
February 9th, 2010
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product’s efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology’s Journal …
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)